Table 2.

Univariate analyses for OS and PFS

VARIABLE	OS [median, 95% IC]	p value	PFS [median, 95% IC]	p value
Diagnosis
MDS	20 (1–42)	0.19	4 (2–20)	0.21
AML	7 (1–17)		4 (1–7)
Cytogenetics
Poor prognosis	14 (4–10)	0.06	2 (2–5)	0.07
Interm/good	20 (14–25)		5 (1–7)
Previous treatment
Untreated	15 (6–24)	0.29	4 (3–6)	0.26
Pretreated	20 (15–25)		20 (1–42)
Courses until response
=1	15 (1–30)	0.82	4 (2–6)	0.56
> 1	15 (3–27)		4 (0.4–7)
Total courses received
≥ 12	20 (12–27)	0.043	4 (1–16)	0.06
< 12	5 (1–18)		4 (2–6)
Reason to stop HMA
Per protocol	34 (1–79)	0.012	20 (1–38)	0.1
Own decision	10 (1–19)		4 (2–6)

OS, overall survival; PFS, progression-free survival; MDS, myelodysplastic syndromes; AML, acute myeloid leukemia; HMA, hypomethylating agents.